Home » Pipeline
Pipeline
June 24, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Cellular Biomedicine Group Inc. | anti-CD20 CAR-T | diffuse large B-cell lymphoma (DLBCL) | Phase I trial initiated enrolling 12 subjects in China |
| Boehringer Ingelheim OSE Immunotherapeutics SA |
SIRPα antagonist monoclonal antibody BI 765063 (formerly OSE-172) | advanced solid tumors | Phase I trial initiated |
| Rocket Pharmaceuticals, Inc. | RP-A501 | Danon disease | Phase I trial initiated enrolling 12-24 pediatric and young adult male subjects |
| BioNTech SE Genmab A/S |
DuoBody-PD-L1x4-1BB | metastatic or unresectable malignant solid tumors | Phase I/IIa trial initiated |
| Reistone Biopharma Company | SHR0302 | Ulcerative Colitis | Phase II trial initiated |
| Reistone Biopharma Company | SHR0302 | Crohn's disease | Phase II trial initiated |
| Zydus Cadila | Saroglitazar Magnesium | Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH) | Phase II trial initiated enrolling 104 subjects at 20 sites across the U.S. |
| InflaRx N.V. | IFX-1 | Pyoderma Gangraenosum (PG) | Phase IIa trial initiated enrolling 12 subjects with moderate to severe PG at three sites in Canada |
| Corvidia Therapeutics Inc. | Ziltivekimab (previously known as COR-001) | advanced chronic kidney disease (CKD) | Phase IIb trial initiated enrolling 240 subjects at 50 sites across the U.S. |
| Arena Pharmaceuticals, Inc. | etrasimod 2 mg | ulcerative colitis (UC) | Phase III trial initiated enrolling subjects with moderately to severely active UC |
| OxThera AB | Oxabact | Primary Hyperoxaluria | Phase III trial initiated enrolling 22 subjects at 10 sites across Europe and the U.S. |
| Torque | TRQ-1501 | relapsed or refractory solid tumors and lymphomas that express any of five tumor-associated antigens (PRAME, WT-1, SSX2, Survivin and NY-ESO-1) | Fast Track designation granted by the FDA |
| Bio-Techne | ExoDx Prostate IntelliScore (EPI) test | prostate cancer | Breakthrough Device designation granted by the FDA |
| Camurus | CAM2029 | acromegaly | IND approval granted by the FDA |
| Triumvira Immunologics, Inc. | TAC01-CD19 | CD19-postive B-cell malignancies | IND approval granted by the FDA |
| Amgen Allergan plc |
KAJINTI (trastuzumab-anns) | HER2-overexpressing adjuvant and metastatic breast cancer | Approval granted by the FDA |
| Amgen Allergan plc |
KAJINTI (trastuzumab-anns) | HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma | Approval granted by the FDA |
| Novo Nordisk | Victoza (liraglutide) | Type 2 diabetes in children and adolescents aged 10-17 years | Approval granted by the FDA |
| Kowa Pharmaceuticals America, Inc. | LIVALO (pitavastatin) | heterozygous familial hypercholesterolemia (HeFH) in subjects eight years and older | Approval granted by the FDA |
